#### ONELAX- docusate sodium liquid Akron Pharma

Disclaimer: Most OTC drugs are not reviewed and approved by FDA, however they may be marketed if they comply with applicable regulations and policies. FDA has not evaluated whether this product complies.

-----

OneLAX Docusate Sodium Liquid 50 mg/5 mL

**Drug Facts** 

# Active ingredient (in each 5 mL)

Docusate Sodium 50 mg

#### Purpose

Stool Softner Laxative

#### Uses

- relieves occasional constipation (irregularity)
- generally produces bowel movement in 12 to 72 hours

### Warnings

**Do Not Use** for more than one week unless directed by a doctor.

### Ask a doctor before use if you

- have stomach pain, nausea or vomiting
- have sudden change in bowel habits that persists over a period of 2 weeks
- are presently taking mineral oil

### Stop use and ask a doctor if

- you have rectal bleeding or fail to have a bowel movement after use of this product. These could be signs of a serious condition.
- a skin rash occurs
- you experience throat irritation

### if pregnant or breast-feeding,

ask doctor before use.

## Keep out of reach of children

In case of accidental overdose, seek medical assistance or contact a Poison Control Center right away.

### Directions

- shake well before using
- follow dosing directions below or use as directed by a physician
- do not exceed recommended dose
- must be given in a 6 oz to 8 oz glass of milk or fruiit juice to prevent throat irritation
- take maximum dose daily until first bowel movement, dosage should then be reduced according to indivisual response

Age	Dose
Adults and children over 12 years of age and over	1 to 6 teaspoons (5 mL - 30 mL)
Children under 12 years of age	Ask a doctor

# Other information

- wach teaspoonful (5 ml) contains: sodium 5 mg
- store at room temperature 15° 30°C (59° 86°F)
- protect from excessive heat
- Pharmacist-preserve and dispense in a tight, light resistant container with a child resistant cap as defined in the USP
- Temper -Evident: Do not use if foil over bottle opening is torn, broken, or missing

# Inactive ingredients:

Anhydrous citric acid, D&C red#33, Flavor vanilla, Glycerin, Methyl Paraben, Propylene glycol, Propyl paraben, Poloxamer 407, Purified water, Sodium benzoate, Sodium citrate, Sorbitol solution, Sucralose

### **Questions or comments?**

call toll-free 1-877-225-6999

Manufactured for: Akron Pharma, Inc. Fairfield, NJ 07004 www.akronpharma.com

Drug Facts		NDC 71399-0039-	De Drug Facts (cont	inued)	
	rpose		<b>/</b> 1	teaspoonfu	I=5mL
(in each 5 mL)	Opol		Age		Dose
Docusate Sodium 50 mgStool Softener L		HA	Adults and children over 12 ye age and over	ars of	1 to 6 teaspoons (5 mL - 30 mL)
Uses relieves occasional constipation (irregularity) generally produces bowel movement in 12 to 72 t			Children under 12 years of age	,	Ask a doctor
Warnings			Other informatio each teaspoonful	n (5ml) con	tains: sodium 5 mg
<b>Do Not Use</b> for more than one week unless directed		F F	store at room tem	perature 1	5° - 30°C (59° - 86°F)
a doctor.			protect from excess		lispense in a tight, light
Ask a doctor before use if you have stomach pain, nausea or vomiting					ild resistant cap as
have sudden change in bowel habits that persists	over a SUDIUIVI		defined in the USF	0	
eriod of 2 weeks ■ are presently taking mineral oil			Temper-Evident: I is torn, broken, or		e if foil over bottle openi
Stop use and ask a doctor if	— LIQUI		Inactive ingredie	-	vdrous citric acid.
■ you have rectal bleeding or fail to have a bowel			D&C red#33 Flavor	r vanilla, G	lycerin, Methyl Paraben
movement after use of this product. These could be signs of a serious condition.	(Docusate Sodiu	m 50 mg/5 ml	Propylene glycol, Pr		
a skin rash occurs		TENED	Purified water, Sodiu Sorbitol solution, Su		ite, Sodium citrate,
you experience throat irritation	STOOL SOF	IENEN	Questions or con		,
If pregnant or breast-feeding, ask a doctor before u Keep out of reach of children. in case of accidental			call toll-free 1-87	7-225-69	999
overdose, seek medical assistance or contact a Pois Control Center right away.	on				
Directions shake well before using	TAMPER EVIDENT: FOR YOUR F	PROTECTION THE CHILD			
follow dosing directions below or use as directed physician	by a RESISTANT CAP HAS A PRINTE THE NECK. DO NOT ACCEPT IF				
do not exceed recommended dose			<b>Akrá</b> n Pharma		
must be given in a 6 oz to 8 oz glass of milk or fru to prevent throat irritation	uit juice		AKr I Plarina Manufactured for:		
take maximum dose daily until first bowel movem	ent.		Akron Pharma, Inc.		
descence also wild there has under a discounting the field of the					
dosage should then be reduced according to individu response	Jal		Fairfield, NJ 07004 www.akronpharma.cor	n 3	71399 00396
dosage should then be reduced according to individu response	16 FL OZ (473 mL)			m 3	<b>1111    1111    111</b> 71399 <b>  </b> 00396   <b> </b>
dosage should then be reduced according to individu response ONELAX docusate sodium liquid	Jal			m 3	<b>11399</b> 00396
dosage should then be reduced according to individu response ONELAX docusate sodium liquid Product Information	16 FL OZ (473 mL)		www.akronpharma.com		<b>1</b> 1399 00396
dosage should then be reduced according to individu response ONELAX docusate sodium liquid	16 FL OZ (473 mL)	Item Code (So	www.akronpharma.com		1399-0039
dosage should then be reduced according to individu response ONELAX docusate sodium liquid Product Information Product Type	16 FL OZ (473 mL)	Item Code (So	www.akronpharma.com		1399-0039
dosage should then be reduced according to individu response ONELAX docusate sodium liquid Product Information Product Type Route of Administration	16 FL 0Z (473 mL) HUMAN OTC DRUG ORAL	ltem Code (So	www.akronpharma.com		1399-0039
ONELAX docusate sodium liquid Product Information Product Type Route of Administration Active Ingredient/Active	16 FL 0Z (473 mL)		www.akronpharma.co	NDC:7	
dosage should then be reduced according to individu response ONELAX docusate sodium liquid Product Information Product Type Route of Administration Active Ingredient/Active Ingred	16 FL 0Z (473 mL) 16 FL 0Z (473 mL) HUMAN OTC DRUG ORAL ORAL Moiety dient Name		ource) Basis of Stre	NDC:7	Strength
dosage should then be reduced according to individu response ONELAX docusate sodium liquid Product Information Product Type Route of Administration Active Ingredient/Active Ingred	16 FL 0Z (473 mL) 16 FL 0Z (473 mL) HUMAN OTC DRUG ORAL ORAL Moiety dient Name		www.akronpharma.co	NDC:7	
dosage should then be reduced according to individu response ONELAX docusate sodium liquid Product Information Product Type Route of Administration Active Ingredient/Active Ingred DOCUSATE SODIUM (UNII: F05Q2	16 FL 0Z (473 mL) 16 FL 0Z (473 mL) HUMAN OTC DRUG ORAL ORAL Moiety dient Name		ource) Basis of Stre	NDC:7	Strength
dosage should then be reduced according to individu response ONELAX docusate sodium liquid Product Information Product Type Route of Administration Active Ingredient/Active Ingred DOCUSATE SODIUM (UNII: F05Q2	16 FL 0Z (473 mL) 16 FL 0Z (473 mL) HUMAN OTC DRUG ORAL ORAL Moiety dient Name		ource) Basis of Stre	NDC:7	Strength
dosage should then be reduced according to individu response ONELAX docusate sodium liquid Product Information Product Type Route of Administration Active Ingredient/Active Ingred DOCUSATE SODIUM (UNII: F05Q2	HUMAN OTC DRUG ORAL Moiety dient Name T2JA0) (DOCUSATE - UNII:M7		ource) Basis of Stre	NDC:7	<b>Strength</b> 50 mg in 5 m
dosage should then be reduced according to individu response ONELAX docusate sodium liquid Product Information Product Type Route of Administration Active Ingredient/Active Ingred DOCUSATE SODIUM (UNII: F05Q2 Inactive Ingredients ANHYDROUS CITRIC ACID (UNII: 1	16 FL 0Z (473 mL) HUMAN OTC DRUG ORAL Moiety dient Name T2JA0) (DOCUSATE - UNII:M7 Ingredient Name KF417D3PSL)		ource) Basis of Stre	NDC:7	<b>Strength</b> 50 mg in 5 m
dosage should then be reduced according to individu response ONELAX docusate sodium liquid Product Information Product Type Route of Administration Active Ingredient/Active Ingred DOCUSATE SODIUM (UNII: F05Q2 Inactive Ingredients ANHYDROUS CITRIC ACID (UNII: EDECOMPOSE)	16 FL 0Z (473 mL) HUMAN OTC DRUG ORAL Moiety dient Name T2JA0) (DOCUSATE - UNII:M7 Ingredient Name KF417D3PSL)		ource) Basis of Stre	NDC:7	<b>Strength</b> 50 mg in 5 m
dosage should then be reduced according to individu response ONELAX docusate sodium liquid Product Information Product Type Route of Administration Active Ingredient/Active Ingred DOCUSATE SODIUM (UNII: F05Q2 Inactive Ingredients ANHYDROUS CITRIC ACID (UNII: 1 D&C RED NO. 33 (UNII: 9DBA0SBI GLYCERIN (UNII: PDC6A3C00X)	HUMAN OTC DRUG ORAL Moiety dient Name T2JA0) (DOCUSATE - UNII:M7 Ingredient Name XF417D3PSL) BOL)		ource) Basis of Stre	NDC:7	<b>Strength</b> 50 mg in 5 m
dosage should then be reduced according to individu response ONELAX docusate sodium liquid Product Information Product Type Route of Administration Active Ingredient/Active Ingred DOCUSATE SODIUM (UNII: F05Q2 Inactive Ingredients ANHYDROUS CITRIC ACID (UNII: 1 D&C RED NO. 33 (UNII: 9DBA0SBI GLYCERIN (UNII: PDC6A3C0OX) METHYLPARABEN (UNII: A218C7HI	HUMAN OTC DRUG ORAL Moiety dient Name T2JA0) (DOCUSATE - UNII:M7 Ingredient Name XF417D3PSL) BOL)		ource) Basis of Stre	NDC:7	<b>Strength</b> 50 mg in 5 m
dosage should then be reduced according to individu response ONELAX docusate sodium liquid Product Information Product Type Route of Administration Active Ingredient/Active Ingred DOCUSATE SODIUM (UNII: F05Q2 Inactive Ingredients ANHYDROUS CITRIC ACID (UNII: E D&C RED NO. 33 (UNII: 9DBA05B) GLYCERIN (UNII: PDC6A3C00X) METHYLPARABEN (UNII: A218C7HI PROPYLENE GLYCOL (UNII: 6DC94	Initial       16 FL 0Z (473 mL)         HUMAN OTC DRUG       ORAL         ORAL       ORAL         Moiety       OIGIENT Name         T2JA0) (DOCUSATE - UNII:M7         Ingredient Name         XF417D3PSL)         BOL)         9T)         Q167V3)		ource) Basis of Stre	NDC:7	<b>Strength</b> 50 mg in 5 m
dosage should then be reduced according to individu response ONELAX docusate sodium liquid Product Information Product Type Route of Administration Active Ingredient/Active Ingred DOCUSATE SODIUM (UNII: F05Q2 Inactive Ingredients ANHYDROUS CITRIC ACID (UNII: EDCGA3C00X) METHYLPARABEN (UNII: A218C7HI PROPYLENE GLYCOL (UNII: 6DC9 PROPYLPARABEN (UNII: Z81X2SC3	Initial       Initia       Initial       Initial		ource) Basis of Stre	NDC:7	<b>Strength</b> 50 mg in 5 m
ONELAX docusate sodium liquid Product Information Product Type Route of Administration Active Ingredient/Active	Initial       Initia       Initial       Initial		ource) Basis of Stre	NDC:7	<b>Strength</b> 50 mg in 5 m

WATER (UNII: 059QF0K00R)

DDIUM BENZOAT	- (-····· -)- ···,					
ODIUM CITRATE (	UNII: 1Q73Q2JULR)					
ORBITOL SOLUTI	<b>ON</b> (UNII: 8KW3E207O2)					
JCRALOSE (UNII: 9	96K6UQ3ZD4)					
Packaging						
Item Code	Package Description	Marketing Start Date	Marketing End Date			
		08/04/2023				
larketing l	nformation					
<b>larketing l</b> Marketing Category	nformation Application Number or Monograph Citation	Marketing Start Date	Marketing End Date			
	DRBITOL SOLUTI JCRALOSE (UNII: 9 ackaging Item Code NDC:71399-	Item Code         Package Description           NDC:71399-         473 mL in 1 BOTTLE; Type 0: Not a Combination	DRBITOL SOLUTION (UNII: 8KW3E20702)         JCRALOSE (UNII: 96K6UQ3ZD4)         ackaging         Item Code       Package Description       Marketing Start Date         NDC:71399-       473 mL in 1 BOTTLE; Type 0: Not a Combination       08/04/2023			

# Labeler - Akron Pharma (067878881)

Revised: 8/2023

Akron Pharma